PeriCor

Executive Summary

PeriCor is a San Diego-based medical device company founded in 2016 with a mission to develop minimally invasive alternatives for pediatric and adult cardiac procedures, including pacemaker implantation, defibrillator placement, and cardiac ablation. The company was founded by Charles Berul, Axel Krieger, Justin Opfermann, and Bradley Clark, bringing together expertise in pediatric cardiology, robotics, and medical device engineering. Traditional cardiac interventions often require open-chest surgery, which carries higher risks and longer recovery times, especially for children. PeriCor's technology aims to enable percutaneous (through the skin) or catheter-based approaches, reducing trauma, hospital stays, and complications. While still in an early stage of development, the company has not disclosed specific product details, funding rounds, or clinical data. However, the founding team's background and the clear unmet need in pediatric interventional cardiology position PeriCor as a promising innovator in the cardiovascular device space. The company is privately held and appears to be pre-revenue, focusing on research and development to advance its novel platform. PeriCor operates in the competitive cardiovascular medical device market, where established players dominate but niche opportunities exist for disruptive technologies. The company's success hinges on demonstrating preclinical safety and efficacy, securing regulatory approvals, and attracting strategic partnerships or Series A funding. Key risks include technical challenges in miniaturizing devices for pediatric patients, lengthy regulatory pathways, and competition from existing minimally invasive techniques. Despite these uncertainties, PeriCor's specialized focus on pediatric cardiac interventions addresses a significant gap in the market, as few companies concentrate on children's heart devices. If successful, PeriCor could transform care for congenital heart disease patients, offering less invasive options from infancy through adulthood. The next 12-24 months will be critical for the company to achieve key development milestones and validate its technology.

Upcoming Catalysts (preview)

• Q4 2026Completion of Preclinical Animal Studies60% success
• Q2 2027Series A Funding Round40% success
• Q1 2028First-In-Human Feasibility Trial Initiation30% success